Motilal Oswal Financial Services has reiterated a BUY rating on Physicswallah after a three-day investor roadshow in Singapore with co-founder Prateek Maheshwari.
News in Focus
Featured, India Business, Analyst View, Stock Markets, ICICI Securities, India, Retail Sector, Zomato
ICICI Securities has maintained a BUY on Eternal, the Blinkit and food-delivery parent formerly known as Zomato, raising its target to Rs 425 from Rs 360 against a current price of Rs 329 — about 2
Featured, India Business, Analyst View, Stock Markets, FMCG Sector, India, Motilal Oswal, Tata Consumer Products
Motilal Oswal has reiterated its BUY call on Tata Consumer Products with a target price of Rs 1,230, implying 27% upside from the current market price of Rs 969.
Ask someone to picture a trip to India and the images arrive quickly: temples with carved towers, hill forts, palace courtyards, crowded markets, street food and festivals that spill into the roads
Featured, Analyst View, Futures & Options, Stock Markets, Banking Sector, Axis Securities, HDFC Bank, India
Axis Securities has issued a BUY call on HDFC Bank in its Axis PUNCH series, setting a three-to-six-month target of Rs 785 against a current price of Rs 715 — about 10 percent of upside.
Apple CEO John Ternus has assumed an unusually hands-on role in the company’s design operations, effectively becoming its de facto design chief while choosing not to appoint a formal successor to J
Main Regional Stories
The gap between the leading artificial intelligence models developed in the United States and China has narrowed to its smallest level on record, according to Bloomberg Intelligence.
OpenAI’s latest product is designed to shift artificial intelligence from a responsive chatbot into a persistent digital worker.
Axis Securities has reiterated a BUY rating on Ethos, India's largest luxury-watch retailer, with a target of Rs 3,360 against a current price of Rs 2,525 — about 33 percent of upside.
Featured, India Business, Analyst View, Stock Markets, ICICI Direct, India, Pharmaceutical Sector, Symbiotec Pharmalab
ICICI Securities has initiated coverage on Symbiotec Pharmalab with a BUY rating and a Conviction Pick tag, setting a 12-month target of Rs 1,540 against a current price of Rs 1,200 — about 28 percent of upside.
